Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li, Liu Cao, Ge Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2785-2793
Closed Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 95
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
Liyan Yang, Zhonglei Wang
Biomedicines (2021) Vol. 9, Iss. 6, pp. 689-689
Open Access | Times Cited: 88
An update review of emerging small-molecule therapeutic options for COVID-19
Dengke Tian, Yuzhi Liu, Chengyuan Liang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 137, pp. 111313-111313
Open Access | Times Cited: 62
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
Jared Pitts, Jiani Li, Jason K. Perry, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 6
Open Access | Times Cited: 60
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines
Séverine Tasker, Diane Addie, Herman Egberink, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1847-1847
Open Access | Times Cited: 32
Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS‐441524
Sally J. Coggins, Jacqueline M. Norris, Richard Malík, et al.
Journal of Veterinary Internal Medicine (2023) Vol. 37, Iss. 5, pp. 1772-1783
Open Access | Times Cited: 21
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
Thuc Nguyen Dan, Kim Donckers, Laura Vangeel, et al.
Antiviral Research (2021) Vol. 192, pp. 105122-105122
Open Access | Times Cited: 54
Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain
Xiaomin Ni, Martin Schröder, Vincent Oliéric, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 4, pp. 603-609
Open Access | Times Cited: 42
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 29
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Liu Cao, Yingjun Li, Sidi Yang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 661
Open Access | Times Cited: 29
A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo
Jasper Fuk‐Woo Chan, Yoo Jin Oh, Shuofeng Yuan, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 10, pp. 100774-100774
Open Access | Times Cited: 29
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal
Kunal Nepali, Ram Lal Sharma, Sachin Sharma, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 28
Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
S. Chiba, Maki Kiso, Noriko Nakajima, et al.
mBio (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 27
Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements
John N. Snouwaert, Leigh A. Jania, Trang Thi Huyen Nguyen, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 2, pp. e1011168-e1011168
Open Access | Times Cited: 15
Stereoretentive Conversion to C-Glycosides from S-Glycosides via Ligand-Coupling on Sulfur(IV)
Qian Yang, Miaomiao Wen, Yu-Jun Ruan, et al.
Organic Letters (2025) Vol. 27, Iss. 4, pp. 954-960
Closed Access
The impact of remdesivir on SARS-CoV-2 evolution in vivo
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, et al.
JCI Insight (2025)
Open Access
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Anti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses
Tiefeng Xu, Kun Li, Siyao Huang, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
Zhonglei Wang, Liyan Yang, Xian‐En Zhao
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 4684-4701
Open Access | Times Cited: 36
Drug Repurposing Against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Sarah Aherfi, Bruno Pradines, Christian Devaux, et al.
Future Microbiology (2021) Vol. 16, Iss. 17, pp. 1341-1370
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top